journal article·2024-03

Ultrathin Clay Nanoparticles‐Mediated Mutual Reinforcement of Ferroptosis and Cancer Immunotherapy

Jianping Liu, Jiezhao Zhan, Ye Zhang, Lin Huang, Jing Yang, Jie Feng, Lingwen Ding, Zheyu Shen, Xiaoyuan Chen

Advanced Materials· Volume 36· Issue 9
Publisher page

Abstract

Abstract Ferroptosis‐triggered immunogenic cell death (ICD) is widely adopted to potentiate the body's antitumor immunity by catalyzing the production of toxic reactive oxygen species (ROS). However, the efficacy of ferroptosis and immunotherapy is greatly restricted by intracellular abundant glutathione (GSH) and immunosuppressive tumor microenvironment (TME). Herein, a facile bottom‐up method for solvent‐free synthesis of ultrathin manganese (Mn)‐based layered double hydroxide nanosheets with high loading efficiency for pro‐inflammatory cytokine interferon (IFNγ) (IFNγ/uMn‐LDHs) is proposed to mutually reinforce the ferroptosis and systemic immunity. The introduction of manganese ions significantly contributes to GSH depletion and hydroxyl radical generation, which can be further enhanced by IFNγ delivery‐induced SLC7A11 downregulation. The ICD effect after cell ferroptosis cooperates with the intrinsic immunomodulatory property of IFNγ/uMn‐LDHs to facilitate the maturation of dendritic cells (DCs) and the priming of T cells. IFNγ secretion from activated CD8+ T cells in turn involves cascade immunogenic ferroptosis, thus constructing a closed‐loop therapy. Remarkably, a potent abscopal effect is observed in the growth inhibition of both primary and distant tumors. Overall, the ultrathin Mn‐based clay nanoplatform provides a simple approach for mutual regulation between ferroptosis and antitumor immune response, overcoming the obstacles of current cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Extracellular vesicles in disease · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biomedical Engineering Southern Medical University Guangzhou Guangdong 510515 P. R. China

Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering Yong Loo Lin School of Medicine and College of Design and Engineering National University of Singapore Singapore 119074 Singapore

Nanomedicine Translational Research Program Yong Loo Lin School of Medicine National University of Singapore Singapore 117597 Singapore

Department of Pathology Yong Loo Lin School of Medicine National University of Singapore Singapore 119074 Singapore

Institute of Molecular and Cell Biology Agency for Science, Technology, and Research (A*STAR) 61 Biopolis Drive, Proteos Singapore 138673 Singapore

Clinical Imaging Research Centre Centre for Translational Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore 117599 Singapore

Funding

National University of Singapore · National Medical Research Council · National Research Foundation · National Natural Science Foundation of China

References (38)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1038/s44222-022-00004-610.1038/s44222-022-00004-6 ↗
3. 10.1038/s41586-023-06063-y10.1038/s41586-023-06063-y ↗
4. 10.1038/s41551‐023‐01083‐510.1038/s41551‐023‐01083‐5 ↗
5. 10.1021/jacs.2c1368910.1021/jacs.2c13689 ↗
6. 10.1126/sciadv.abe717410.1126/sciadv.abe7174 ↗
7. 10.1021/acsnano.2c1035210.1021/acsnano.2c10352 ↗
8. 10.1038/s41467-022-31044-610.1038/s41467-022-31044-6 ↗
9. 10.1016/j.nantod.2022.10155210.1016/j.nantod.2022.101552 ↗
10. 10.1002/adma.20220978510.1002/adma.202209785 ↗
11. 10.1038/s41551-021-00831-910.1038/s41551-021-00831-9 ↗
12. 10.1126/sciadv.abm103210.1126/sciadv.abm1032 ↗
13. 10.1002/adfm.20230146210.1002/adfm.202301462 ↗
14. 10.1002/anie.20211524710.1002/anie.202115247 ↗
15. 10.1021/acsnano.2c1089310.1021/acsnano.2c10893 ↗
16. 10.1038/s41586-019-1170-y10.1038/s41586-019-1170-y ↗
17. 10.1089/jir.2013.006710.1089/jir.2013.0067 ↗
18. 10.1038/s41423-021-00735-310.1038/s41423-021-00735-3 ↗
19. 10.1021/acsnano.3c0463210.1021/acsnano.3c04632 ↗
20. 10.1002/anie.20200511110.1002/anie.202005111 ↗
21. 10.1002/adma.20210374810.1002/adma.202103748 ↗
22. 10.1021/acsnano.2c0664610.1021/acsnano.2c06646 ↗
23. 10.1016/j.nantod.2022.10140510.1016/j.nantod.2022.101405 ↗
24. 10.1021/acsnano.3c0121510.1021/acsnano.3c01215 ↗
25. 10.1039/D2CS00236A10.1039/D2CS00236A ↗
26. 10.1038/s41467-022-31106-910.1038/s41467-022-31106-9 ↗
27. 10.1002/adma.20170738910.1002/adma.201707389 ↗
28. 10.1039/C7CS00318H10.1039/C7CS00318H ↗
29. 10.1016/j.jconrel.2021.05.01110.1016/j.jconrel.2021.05.011 ↗
30. 10.1002/adma.20140257210.1002/adma.201402572 ↗
31. 10.1158/2159-8290.CD-19-033810.1158/2159-8290.CD-19-0338 ↗
32. 10.1161/CIRCRESAHA.120.31650910.1161/CIRCRESAHA.120.316509 ↗
33. 10.1038/s41467-021-27414-110.1038/s41467-021-27414-1 ↗
34. 10.1038/nature0847610.1038/nature08476 ↗
35. 10.1038/s41565-022-01134-z10.1038/s41565-022-01134-z ↗
36. 10.1038/s41565-021-00962-910.1038/s41565-021-00962-9 ↗
37. 10.1016/j.nantod.2022.10167010.1016/j.nantod.2022.101670 ↗
38. 10.1002/adma.20210826310.1002/adma.202108263 ↗